$40 Million for Paratek Pharmaceuticals


Paratek Pharmaceuticals of Boston announced it has closed the first tranche of a $40 million financing round. (It’s a Series H round, according to peHUB.) The company says it will use the funds in part to further the development of antibiotics to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant bacteria.

By posting a comment, you agree to our terms and conditions.